Tag - AXNX

Developments

FDA approves Axonics sacral neuromodulation system

Axonics Modulation Technologies (NASDAQ:AXNX) received FDA premarket approval for its rechargeable-sacral neuromodulation (r-SNM) system for overactive bladder (OAB) and urinary retention indications. The r-SNM system...

November 14, 2019

Markets

SVB Leerink starts Axonics Modulation at OP; PT $45

SVB Leerink initiated coverage of Axonics Modulation Technologies (NASDAQ:AXNX) with an “outperform” rating and $45 price target. The stock closed at $30.27 on Sept. 16. “To us, Axonics represents a hyper-growth story...

September 17, 2019

Tag - AXNX

FDA approves Axonics sacral neuromodulation system

SVB Leerink starts Axonics Modulation at OP; PT $45

General

More